2022 World Conference on Lung Cancer (ePosters)-EP01.01-007. Incorporating cfDNA Detection to CT Scan Assessment in Post-Surgical Lung Cancer Patients

EP01.01-007. Incorporating cfDNA Detection to CT Scan Assessment in Post-Surgical Lung Cancer Patients

Pdf Summary

Liquid biopsies based on plasma cell-free tumour deoxyribonucleic acid (cfDNA) have shown promise in monitoring lung cancer progression. This study aimed to evaluate the role of incorporating cfDNA detection to CT scan assessment in post-surgical early-stage lung cancer patients and assess its usefulness in detecting residual postsurgical cfDNA. <br /><br />The study included 34 patients with early-stage lung cancer. Of these, seven patients showed imageology progression, while 27 did not. The seven patients with confirmed CT scan progression had higher median cfDNA values at last follow-up compared to cfDNA values at surgical discharge. Patients with tumors larger than 3 cm, more than one poor prognostic factor, and histological adenocarcinomas were more likely to experience progression. <br /><br />The absolute values of cfDNA quantification showed that the mean time to molecular relapse was 343.86 days, while the mean time for CT progression was 647 days. Before imageology progression, molecular evidence showed metabolic cancer activity with a gradual increase in cfDNA levels. <br /><br />The study suggests that early cfDNA detection, in conjunction with CT scan assessment, has a prognostic role in post-surgical lung cancer patients. Early clearance of cfDNA is associated with better survival outcomes, and cfDNA relapse can be quantified and confirmed later by CT scan.<br /><br />Overall, incorporating cfDNA detection into CT scan assessment may be useful in monitoring surgically resectable lung cancer and detecting residual postsurgical cfDNA. This approach could potentially improve the management and outcomes of early-stage lung cancer patients.

Asset Subtitle

Joana Espiga De Macedo, Portugal

Meta Tag

Speaker Joana Espiga De Macedo, Portugal

Topic Early Detection and Screening - Biomarkers

Keywords

liquid biopsies

cfDNA

lung cancer progression

CT scan assessment

early-stage lung cancer patients

residual postsurgical cfDNA

molecular relapse

metabolic cancer activity

survival outcomes

incorporating cfDNA detection